Company(ies): Daiichi Sankyo
Principal Therapy Area: Cancer
The humanised monoclonal antibody, tigatuzumab (CS-1008; TRA-8), targets the tenth member of the tumor necrosis factor receptor superfamily (TNFRSF10B), which is also known as death receptor 5 (DR5) or TRAIL receptor 2, and which is overexpressed on the cell surface of many types of tumours. Tigatuzumab induces apoptosis of these cells and accordingly, is being studied in a number of cancers with cells expressing DR5 on the cell surface.
The compound was discovered by joint research between Sankyo and the University of Alabama, and preclinical studies have shown an anticancer effect in vitro and in vivo.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Customers focusing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for firstname.lastname@example.org